G
Glenn M. Chertow
Researcher at Stanford University
Publications - 830
Citations - 94517
Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.
Papers
More filters
Journal Article
Calcium on trial: Beyond a reasonable doubt? Authors' reply
Caterina Canavese,Daniela Bergamo,Hamido Dib,Francesca Bermond,Manuei Burdese,Albert Fournier,Mohamed Benyahia,Crina Popa Claudia,Tarek Sadek,Mark Vb Cleveland,Charles R. Nolan,Wajeh Y. Quinibi,Glenn M. Chertow,Steven K. Burke,Paolo Raggi +14 more
Journal ArticleDOI
MO532: Cardiovascular Events in Patients With Non–Dialysis-Dependent Chronic Kidney Disease and Anemia: Regional Analysis of Patients Previously Treated With Erythropoiesis-Stimulating Agents in the PRO2TECT Trial
Patrick S. Parfrey,Glenn M. Chertow,Kai-Uwe Eckardt,Steven K. Burke,Wenli Luo,T. Minga,Wolfgang C. Winkelmayer +6 more
TL;DR: Regional differences in MACE in patients with NDD-CKD-administered vadadustat and darbepoetin alfa who were previously treated with erythropoietin-stimulating agents (ESAs) in the PRO2TECT trials were investigated.
Journal ArticleDOI
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
John J.V. McMurray,David C. Wheeler,Bergur V. Stefánsson,Niels Jongs,Douwe Postmus,Ricardo Correa-Rotter,Glenn M. Chertow,Fan Fan Hou,Peter Rossing,C. David Sjöström,Scott D. Solomon,Robert D. Toto,Anna Maria Langkilde,Hiddo J.L. Heerspink,Dapa-Ckd Trial Committees,Investigators +15 more
TL;DR: The DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial as mentioned in this paper investigated the effects of DAPAGLOIN in chronic kidney disease patients, with and without heart failure (HF).
Journal ArticleDOI
Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients
Wolfgang C. Winkelmayer,Susan Arnold,Steven K. Burke,Glenn M. Chertow,Kai-Uwe Eckardt,Alan G. Jardine,Eldrin F. Lewis,Wenli Luo,Kunihiro Matsushita,Peter A. McCullough,T. Minga,Patrick S. Parfrey +11 more
TL;DR: In this article , the authors compared the safety of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD).